Pricing Log in Create free account

Mineralys Therapeutics, Inc. (MLYS) vs Sarepta Therapeutics, Inc. (SRPT)

Mineralys Therapeutics, Inc. and Sarepta Therapeutics, Inc. are both Biotechnology companies. Mineralys Therapeutics, Inc. and Sarepta Therapeutics, Inc. are of similar size ($1.9B and $1.9B). Mineralys Therapeutics, Inc. has the higher net margin (0.00% vs −6.93%) and the higher return on invested capital (0.00% vs −5.64%). Across the 13 metrics below, Sarepta Therapeutics, Inc. leads on 7 and Mineralys Therapeutics, Inc. on 6.

Valuation

Metric MLYS SRPT Biotechnology median
P/E n/m n/m 8.50
P/S n/m 0.91 9.71
P/B 3.12 1.18 2.13
Price to free cash flow n/m 23.99 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 0.99 9.21
Earnings yield (20.89%) (8.46%) (33.15%)
Free cash flow yield (8.07%) 4.17% (25.50%)

Profitability

Metric MLYS SRPT Biotechnology median
Gross margin — 59.09% 65.16%
Operating margin 0.00% (7.26%) 0.00%
Net margin 0.00% (6.93%) 0.00%
Free cash flow margin 0.00% 3.80% 0.00%
Return on equity (80.88%) (9.48%) (56.36%)
Return on assets (69.67%) (3.98%) (48.04%)
Return on invested capital 0.00% (5.64%) 0.00%

Growth

Metric MLYS SRPT Biotechnology median
Revenue growth (TTM) — (20.44%) 6.02%
EPS growth (last fiscal year) 37.43% (404.70%) 30.26%
Revenue growth, 5-year CAGR — 32.41% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MLYS SRPT Biotechnology median
Debt to equity 0.18 0.55 0.00
Current ratio 34.46 4.42 4.72
Net debt to EBITDA 3.85 0.17 0.96

Dividend

Metric MLYS SRPT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MLYS SRPT Biotechnology median
Market cap 1.91b 1.88b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack